[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605663":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":57,"collaborators":25,"id":60,"slug":25,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":25,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":25,"enrollmentInfo":68,"targetDuration":25,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":25,"overallStatus":37,"whyStopped":25,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"B-CAP group","EXPERIMENTAL","Patients will a 10-day course of bismuth, metronidazole, tetracycline four times daily, and vonoprazan 20 mg twice daily.",[13],"Drug: Potassium-Competitive Acid Blocker",{"label":15,"type":16,"description":17,"interventionNames":18},"PPI group","ACTIVE_COMPARATOR","Patients will receive a 10-day course of bismuth, metronidazole, tetracycline four times daily, and rabeprazole 20 mg twice daily.",[19],"Drug: Proton Pump Inhibitor",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Potassium-Competitive Acid Blocker",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"Proton Pump Inhibitor",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Mohamed G Flefel, MD","CONTACT","00201009156988","mohamed.galal@med.tanta.edu.eg",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Tanta","El-Gharbia","31527","Egypt",{"type":43,"coordinates":44},"Point",[45,46],31.00192,30.78847,{"lat":46,"lon":45},[49,50,53,55],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},{"name":51,"role":52,"phone":25,"phoneExt":25,"email":25},"Nashwa S Abdeen, MD","PRINCIPAL_INVESTIGATOR",{"name":54,"role":52,"phone":25,"phoneExt":25,"email":25},"Ashraf A Aboismail, MD",{"name":56,"role":52,"phone":25,"phoneExt":25,"email":25},"Ahmed F Selim, MD",{"type":52,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Mohamed Galal Flefel","Lecturer of Internal Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.","100605663",false,"NCT07165444","Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection","Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Both sexes.\n* Confirmed Helicobacter pylori infection by stool antigen (3rd-gen ELISA) or urea breath test (UBT).\n* No prior eradication therapy.\n\nExclusion Criteria:\n\n* Prior Helicobacter pylori treatment.\n* Use of antibiotics, proton pump inhibitor, or bismuth in the prior 4 weeks.\n* Gastric surgery history.\n* Major organ failure.\n* Pregnancy or lactation.\n* Known allergy to study drugs.","ALL","18 Years",{"count":69,"type":70},320,"ESTIMATED","INTERVENTIONAL",[73],"NA","This study aims to compare the eradication rate, safety, and patient adherence between potassium-competitive acid blockers (P-CABs) and proton pump inhibitor-based bismuth quadruple therapy in patients with Helicobacter pylori infection.",[23,27,76,77,78],"Bismuth Based Quadruple Therapy","Treatment","Helicobacter Pylori Infection","2025-09-11",{"date":81,"type":82},"2025-09-12","ACTUAL",{"date":79,"type":82},{"date":85,"type":70},"2026-02-01",{"name":5,"class":6},1]